In Brief: Bristol-Myers Squibb Taxol
Executive Summary
Bristol-Myers Squibb Taxol: Oncologic Drugs Advisory Committee will review two paclitaxel supplemental indications on March 20: first-line treatment for advanced carcinoma of the ovary in the morning, and treatment of non-small cell lung cancer in patients who are not candidates for radiotherapy in the afternoon...